The Journal of Nutritional Biochemistry
Volume 10, Issue 11 , Pages 670-673 , November 1999

Cefetamet pivoxil treatment causes loss of carnitine reserves that can be prevented by exogenous carnitine administration

  • Maria Pap

      Affiliations

    • Department of Pediatrics University Medical School of Pécs, Pécs, Hungary
    • ,
  • Gábor Kopcsányi

      Affiliations

    • Department of Pediatrics University Medical School of Pécs, Pécs, Hungary
    • ,
  • Loran L Bieber

      Affiliations

    • Department of Biochemistry, Michigan State University, East Lansing, MI USA
    • ,
  • Douglas A Gage

      Affiliations

    • Department of Biochemistry, Michigan State University, East Lansing, MI USA
    • ,
  • Béla Melegh

      Affiliations

    • Department of Pediatrics University Medical School of Pécs, Pécs, Hungary
    • Department of Medical Genetics and Child DevelopmentUniversity Medical School of Pécs, Pécs, Hungary
    • MTA-POTE Clinical Genetics Research Group of Hungarian Academy of Sciences, University Medical School of Pécs, Pécs, Hungary

Received 2 March 1999 ,Accepted 2 March 1999.

References 

  1. Bieber LL. Carnitine. Ann. Rev. Biochem. 1988;57:261–283
  2. Bieber LL, Emaus R, Valkner K, Farrel S. Possible functions of short-chain and medium-chain carnitine acetyl-transferases. Fed. Proc. 1982;41:2858–2862
  3. Bremer J. Carnitine (Metabolism and functions). Physiol. Rev. 1983;63:1440–1480
  4. Melegh B, Kerner J, Bieber LL. Pivampicillin-promoted excretion of pivaloylcarnitine in humans. Biochem. Pharmacol. 1987;36:3405–3409
  5. Melegh B, Kerner J, Jaszai V, Bieber LL. Differential excretion of xenobiotic acyl-esters of carnitine due to administration of pivampicillin and valproate. Biochem. Med. Metab. Biol. 1990;43:30–38
  6. Quistad GB, Staiger LE, Schooley DA. The role of carnitine in the conjugation of acidic xenobiotics. Drug Metab. Dispos. 1986;14:521–526
  7. Vickers S, Duncan CAH, White SD, Ramjit HG, Smith JL, Walker RW, et al. Carnitine and glucuronic acid conjugates of pivalic acid. Xenobiotica. 1985;15:53–458
  8. Melegh B, Pap M, Molnar D, Masszi G, Kopcsanyi G. Carnitine administration ameliorates the changes in energy metabolism caused by short-term pivampicillin treatment. Eur. J. Pediatr. 1997;156:759–799
  9. Diep QN, Bohmer T, Holme JI, Torvik A, Storrosten OT, Loeaecken CV, et al. Slow replenishment of carnitine deficiency after cessation of long-term treatment with pivaloyl-containing antibiotics. Pharm. World Sci. 1993;15:225–229
  10. Melegh B, Pap M, Morava E, Molnar D, Dani M, Kurucz J. Carnitine-dependent changes of metabolic fuel consumption during long-term treatment with valproic acid. J. Pediatr. 1994;125:317–321
  11. Melegh B, Pap M, Szekely G, Gage DA, Sherry AD, Bieber LL. No replenishment of carnitine from trimethyllysine during pivalate-induced carnitine loss in humans. J. Nutr. Biochem. 1997;8:147–151
  12. Melegh B, Sumegi B, Sherry AD. Preferential elimination of pivalate with supplemental carnitine via formation of pivaloylcarnitine in man. Xenobiotica. 1993;23:1255–1261
  13. Chibante A, Peixoto E, Lejeune R, Winter K, Kissling M. Clinical efficacy and safety of cefetamet pivoxil in toddlers. Int. J. Antimicrob. Agents. 1994;4:203–210
  14. Cullmann W. Comparative evaluation of orally active antibiotics against community-acquired pathogens (Results of eight European countries). Chemotherapy. 1996;42:11–20
  15. Dagan R, Syrogiannopoulos G, Ashkenazi S, Engelhard D, Einhorn M, Gatzolakaravelli M, et al. Parenteral-oral switch in the management of pediatric pneumonia. Drugs. 1994;47(suppl):43–51
  16. Hanson AD, Rathinasabapathi B, Rivoal J, Burnet M, Dillon MO, Gage D. Osmoprotective compounds in the Plumbaginaceae (A natural experiment in metabolic engineering of stress tolerance). Proc. Natl. Acad. Sci. USA. 1994;91:306–310
  17. Holme E, Greter J, Jacobson CE, Lindstedt S, Nordin I, Kristiansson B, et al. Carnitine deficiency induced by pivampicillin and pivmecillinam therapy. Lancet. 1989;2:469–472
  18. Shimizu K, Saito A, Shimada J, Ohmichi M, Hiraga Y, Inamatsu T, et al. Carnitine status and safety after administration of S-1108, a new oral cephem, to patients. Antimicrob. Agents Ch. 1993;37:1043–1049
  19. Totsuka K, Shimizu K, Konishi M, Yamamoto S. Metabolism of S-1108, a new oral cephem antibiotic, and metabolic profiles of its metabolites in humans. Antimicrob. Agents Ch. 1992;36:757–761
  20. Ruff LJ, Brass EP. Metabolic effects of pivalate in isolated rat hepatocytes. Toxicol. Appl. Pharm. 1991;110:295–302
  21. Engel AG, Rebouche CJ. Carnitine metabolism and inborn errors. J. Inherit. Metab. Dis. 1984;7(suppl 1):38–43
  22. Kerner J, Hoppel C. Genetic disorders of carnitine metabolism and their nutritional management. Annu. Rev. Nutr. 1998;18:179–206
  23. Abrahamsson K, Mellander M, Eriksson BO, Holme E, Jodal U, Jonsson A, et al. Transient reduction of human left ventricular mass in carnitine depletion induced by antibiotics containing pivalic acid. Brit. Heart. J. 1995;74:656–659

☆ Supported by grants from the Hungarian National Science Foundation (OTKA T 023560 and T-019301), Ministry of Welfare (ETT T-03 662/93), and Ministry of Education (FKFP 0499/99). Mass spectral data were collected at the MSU-NIH Mass Spectrometry Facility, which is supported in part by a grant from the National Institutes of Health (RR 00480).

PII: S0955-2863(99)00051-0

The Journal of Nutritional Biochemistry
Volume 10, Issue 11 , Pages 670-673 , November 1999

Article Tools

* Image Usage & Resolution